Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
419.1 USD | +0.42% | +0.94% | +3.12% |
Mar. 21 | Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease | MT |
Mar. 21 | Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.12% | 108B | |
+9.93% | 104B | |
+6.38% | 23.66B | |
-11.79% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.04% | 16.19B | |
+4.52% | 13.72B | |
+34.85% | 12.22B | |
-5.90% | 10.36B |
- Stock
- Equities
- Stock Vertex Pharmaceuticals Incorporated - Nasdaq
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals : Morgan Stanley Downgrades Vertex Pharmaceuticals to Underweight from Equalweight, Keeps $202 Price Target